JAK inhibitors (JAKis) are increasingly used in patients with mycosis fungoides (MF)/Sézary syndrome (SS), often given outside intentional lymphoma-directed therapy, yet their real-world impact remains heterogeneous and not well characterized. Our multicentre experience suggests that disease acceleration may occur in specific clinical settings, particularly in patients initially diagnosed with dermatitis who were later recognized as having MF/SS while receiving JAKis, as well as in post-transplant contexts. Symptom-focused benefit, however, may be observed in carefully selected cases. It remains uncertain whether these observations represent a direct drug-related effect. Collectively, these findings highlight that the use of JAKis in MF/SS should be undertaken with caution.
Amitay-Laish et al. (Fri,) studied this question.